Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peritoneal Dialysis I: Introduction and Procedure01:30

Peritoneal Dialysis I: Introduction and Procedure

Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between nephrolithiasis and kidney disease progression in patients with autosomal dominant polycystic kidney disease: a prospective cohort study.

Clinical kidney journal·2026
Same author

Ethical Implementation of Organ Donation Following Medical Assistance in Dying: Recommendations of the Ethics Committee of the Transplantation Society.

Transplantation·2026
Same author

Establishing a core outcome measure for cancer in trials in kidney transplantation: a standardized outcomes in nephrology-kidney transplantation consensus workshop report.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Mast Cell Activation Syndrome and Mimickers.

Immunology and allergy clinics of North America·2026
Same author

Deceased Organ Donation and Transplantation in LIMC: A Meeting Report.

Transplantation·2026
Same author

A school-based respect-for-life program integrating deceased organ donation awareness in South Korea: a post-class mixed-methods evaluation.

Scientific reports·2026

Related Experiment Video

Updated: May 18, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

Biocompatible peritoneal dialysis solution preserves residual renal function.

Sejoong Kim1, Kook-Hwan Oh, Jieun Oh

  • 1Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.

American Journal of Nephrology
|September 26, 2012
PubMed
Summary
This summary is machine-generated.

Biocompatible peritoneal dialysis (PD) solution helps preserve residual renal function (RRF) in continuous ambulatory PD (CAPD) patients over 24 months. This solution also shows potential benefits in correcting metabolic acidosis.

More Related Videos

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

Related Experiment Videos

Last Updated: May 18, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

Area of Science:

  • Nephrology
  • Renal Replacement Therapy
  • Peritoneal Dialysis

Background:

  • Long-term effects of biocompatible peritoneal dialysis (PD) solutions on residual renal function (RRF), inflammation, adipokines, and metabolic acidosis remain debated.
  • This study investigates the extended impact of a biocompatible PD solution in continuous ambulatory PD (CAPD) patients.

Purpose of the Study:

  • To evaluate the long-term effects of biocompatible PD solution (LS) versus conventional PD solution (CS) on RRF, inflammation, and metabolic acidosis in CAPD patients.
  • To assess the preservation of RRF over a 24-month period.

Main Methods:

  • A cohort of 63 incident CAPD patients were followed for 24 months.
  • Patients received either biocompatible PD solution (LS, n=48) or conventional PD solution (CS, n=43).
  • Residual renal function (GFR), effluent markers (CA-125, IL-6), and serum tCO2 levels were monitored.

Main Results:

  • After 24 months, the glomerular filtration rate (GFR) in the LS group was double that of the CS group (33.5 vs. 16.3 l/week/1.73 m²).
  • In patients with initial GFR >2 ml/min/1.73 m², LS group GFR remained significantly higher (43.7 vs. 18.6 l/week/1.73 m²).
  • Effluent CA-125 levels increased in the LS group, while IL-6 levels did not differ; serum tCO2 levels were higher in the LS group.

Conclusions:

  • Biocompatible PD solution (LS) may maintain its effect on preserving RRF over 24 months in CAPD patients.
  • LS use demonstrates potential benefits, including the correction of metabolic acidosis.